AstraZeneca is a Swedish-British multinational pharmaceutical and biotechnology company headquartered in Cambridge, UK. It was formed in 1999 through the merger of Astra AB and Zeneca Group and maintains a global portfolio across major disease areas.
FDA approves AstraZeneca and Daiichi Sankyo's Datroway for first-line TNBC patients not eligible for PD-1/L1 inhibitors, based on Phase III TROPION-Breast02 data showing a 21% reduction in risk of death versus chemotherapy.
Compugen said it will release fourth quarter and full year 2025 results on March 2, 2026, and present at the Needham Virtual Healthcare Conference on April 13. The company also outlined its Phase 1 and Phase 3 immuno-oncology pipeline programs.
The FDA granted orphan drug designation to AstraZeneca’s surovatamig for follicular lymphoma. The status supports development for rare diseases but is only an early regulatory step.
FDA approves Genentech's Tecentriq as first ctDNA-guided adjuvant therapy for muscle-invasive bladder cancer, and Venclexta plus acalabrutinib as first all-oral fixed-duration regimen for CLL.
Vanguard and Goldman Sachs forecasts pointed to stronger long-term returns for international stocks than for U.S. equities. The articles highlighted broad international, European and emerging-market ETFs with low expense ratios and large exposure to non-U.S. markets.
Trump secured agreements with 16 pharmaceutical companies tied to TrumpRx.gov, including most-favoured-nation pricing and direct-to-patient discounts. Several companies disclosed price cuts for obesity, diabetes, insulin and other medicines.
FDA's ODAC voted 6-3 against AstraZeneca's camizestrant for HR+/HER2- metastatic breast cancer, citing uncertain clinical benefit from the SERENA-6 trial design. The FDA raised concerns about the early-switch treatment paradigm and long-term outcomes.
FDA approves AstraZeneca's Breztri Aerosphere as the first single-inhaler triple therapy for asthma in patients aged 12+, based on Phase III KALOS and LOGOS trials showing improved lung function and reduced exacerbations versus dual therapy.
The FDA approved AstraZeneca’s Saphnelo Pen for once-weekly self-administration in adults with systemic lupus erythematosus. Approval was based on Phase III TULIP-SC results showing reduced disease activity versus placebo.
AstraZeneca will report pivotal first-half data on sonesitatug vedotin in Claudin18.2 gastric cancer. The phase 3 Clarity-Gastric01 study is enrolling patients with ≥25% expression.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07597993 |
BEYOND Study: A Multicentre, Prospective, Observational Study of Real-world Treatment Patterns and Outcomes of Trastuzumab Deruxtecan in Patients With HR Positive, HER2-low or Ultra-low Metastatic Breast Cancer Previously Treated With Endocrine Therapy |
NOT_YET_RECRUITING | |
| NCT07593248 |
Real-World Outcomes of Resected EGFR-Mutated NSCLC Patients Treated With Adjuvant EGFR-TKI in China |
NOT_YET_RECRUITING | |
| NCT07593196 |
HER2-positive Metastatic Breast Cancer in Kazakhstan |
NOT_YET_RECRUITING | |
| NCT07590934 |
Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07584083 |
Anifrolumab in Adults With Primary Antiphospholipid Syndrome (AnifAPS Trial) |
NOT_YET_RECRUITING | PHASE2 |
| NCT07571746 |
A Study to Assess the Effect of Surovatamig in Adult Participants With Antibody-mediated Kidney Disease |
RECRUITING | PHASE2 |
| NCT07570394 |
BREZTRI REGULATORY POST MARKETING SURVEILLANCE IN KOREA |
NOT_YET_RECRUITING | |
| NCT07566195 |
Long-term Safety and Tolerability of Tozorakimab in Patients With COPD and History of Exacerbations |
RECRUITING | PHASE3 |
| NCT07560215 |
PROMET-BR - Molecular Profiling of Metastatic Prostate Cancer: a Brazilian Cohort |
NOT_YET_RECRUITING | |
| NCT07546760 |
A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234 |
RECRUITING | PHASE1 |
